Vanda Pharmaceuticals (VNDA) News
NASDAQ: VNDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
4.03-0.21 (-4.95%)
At close: Oct 16, 4:00 PM ET · Delayed 15 min
VNDA news summary
We found 2 recent headlines mentioning Vanda Pharmaceuticals (VNDA): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, PR Newswire. For price context, VNDA is down 4.95% at $4.03. The most recent story, "XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?", was published by Nasdaq on Oct 15, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Vanda Pharmaceuticals headlines
- XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.NasdaqXENE, JNJ, VNDA
- Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramPhase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14,…PR Newswire